Nasdaq
$80.39▲ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.90BShares out 61.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 5d agoAfter-hours26.10.20 05:104Ownership#●●●#●●●
Mirum Pharmaceuticals, Inc.
Insider Jolanda Howe of Mirum Pharmaceuticals reported a change in beneficial ownership of securities as of October 16, 2026. This filing serves as a standard Form 4 disclosure regarding insider equity transactions.…more
$80.39+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:064Ownership
Mirum Pharmaceuticals, Inc.
Insider Robert Paul Myers of Mirum Pharmaceuticals reported a change in beneficial ownership of securities as of October 9, 2026. This filing serves as a formal disclosure of insider transactions via Form 4.…more
$80.39+0.09%vs prev closeView filingShare - 10.13Pre-market26.10.13 21:098-KKey event
Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals announced that its Phase 3 EXPAND study of LIVMARLI (maralixibat) met its primary endpoint and all five prespecified secondary endpoints with statistical significance in patients with ultra-rare cholestatic liver diseases. Based on these results, the company plans to submit a supplemental New Drug Application in the United States in the first half of 2027.…more
$80.39+0.09%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Regular26.10.12 22:38Bullish#●●●#●●●#●●●
Mirum Pharmaceuticals Gains on Positive Phase 3 Trial Results
Mirum Pharmaceuticals announced that its Phase 3 EXPAND study for LIVMARLI successfully met primary and secondary endpoints in treating cholestatic pruritus. The positive clinical data, which demonstrated significant reduction in itching and bile acids, has driven the company's stock price higher.…more
$80.39+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.12Pre-market26.10.12 21:05
●●●●●●●● ●●●●● ●●●●●●
Mirum Pharmaceuticals announced that its Phase 3 EXPAND study for LIVMARLI successfully met its primary and all secondary endpoints in treating rare cholestatic liver diseases. The company plans to submit a supplemental New Drug Application to the FDA in the first half of 2027.…more
$80.39+0.09%vs prev closeShareBenzinga - 9.28Pre-market26.09.28 21:38
●●●●●●●● ●●●●● ●●●●●●
Mirum Pharmaceuticals and Incyte have received FDA approval for Atebrioz, a once-daily oral treatment for fibrodysplasia ossificans progressiva. The drug demonstrated clinical efficacy by significantly reducing the volume of abnormal bone formation in patients.…more
$80.39+0.09%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report